SBS Share Price Performance
€0
-26.00 (-100.00%)
Price €0
Fair Value€20.00
Share Pricen/a
Narrative Update • Jun 02
Stratec SE Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
SBS Community Narratives
AN
Fair Value
·Fair Value €20 10.2% undervalued intrinsic discount
Weak Product Launches Will Drag Performance Despite Emerging Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €28.46 36.9% undervalued intrinsic discount
SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value €34 47.2% undervalued intrinsic discount
Aging Populations And Automation Will Spur Diagnostic Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Weak Product Launches Will Drag Performance Despite Emerging Opportunity
Stratec looks caught between a long-term lift from growing demand for medical testing and a near-term slump as customers delay buying new lab machines and squeeze prices. See what’s keeping growth and cash generation under pressure, and what could change if demand for its newer platforms finally picks up.Read more
AN
€20
10.2% undervalued intrinsic discount
Fair Value
Profit Margin
6.8%
Future PE
14.86x
Price in 2029
€24.01
Aging Populations And Automation Will Spur Diagnostic Demand
Key Takeaways Structural upswing in system demand, operating leverage from automation, and a shift to higher-value products signal underestimated earnings and margin upside. Long-term OEM partnerships and rising emerging market investments position Stratec for sustained top-line growth and enhanced global market share.Read more
AN
€34
47.2% undervalued intrinsic discount
Fair Value
Revenue
6.23% p.a.
Profit Margin
7.61%
Future PE
21.02x
Price in 2029
€41.06
SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Key Takeaways Increased demand for automated diagnostic solutions and consumables positions the company for recurring revenue growth and stronger margins amid healthcare digitalization. Investments in proprietary technologies, regulatory compliance, and operational efficiency are expected to drive long-term growth, margin improvement, and stable earnings.Read more
AN
€28.46
36.9% undervalued intrinsic discount
Fair Value
Revenue
5.19% p.a.
Profit Margin
7.34%
Future PE
18.82x
Price in 2029
€34.43
Trending Discussion
Recently Updated Narratives
AN
SBS: Lowered Multiples And Stable Margins Will Support Future Upside Potential
Fair Value: €20 10.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
Fair Value: €34 47.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Fair Value: €28.46 36.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Stratec SE Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 14, 2026
- -0.02
- 25.60%
- -0.097%
- 50.4%
About SBS
- Founded
- 1979
- Employees
- 1343
- CEO
- WebsiteView website
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
